Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

Experimental cancer drug works differently than researchers originally thought (opens in a new tab)

news-medical.net · 2026-10-06

Short answerEvidenceSource

Short answer

Mixed

Mixed.

The claims we could check match the study, but some claims were not covered by the evidence reviewed.

  • 2 supported
  • 3 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Mixed

Every claim we could check holds up. Two of five claims match the study. This overall rating is based only on the claims we could check. Three claims the study doesn't address.

  • 2 supported
  • 3 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5Not coveredA cancer drug currently being tested in patients may have entered clinical trials based on an incorrect understanding of how it works.View evidenceHide evidence

Why this verdict

The abstract-level paper profile supports that zavondemstat is a clinical analog of QC6352 and that, in glioblastoma models, the antiproliferative mechanism is attributed to DHODH rather than KDM4. However, the supplied paper profile does not establish that zavondemstat is currently being tested in patients, why it entered clinical trials, or that clinical-trial entry was based on an incorrect mechanistic understanding. The lead/headline-style framing is therefore plausible from context but not verifiable from the abstract-depth evidence supplied.

1

Study evidence

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”
2

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”
Claim 2 of 5Not coveredThese findings could affect the interpretation of previous studies that used QC6352 and may have implications for the ongoing clinical development of zavondemstat.View evidenceHide evidence

Why this verdict

The paper profile supports the idea that QC6352’s use as a KDM4 probe may need reinterpretation, because DHODH is identified as the functional target driving its antiproliferative activity and the profile emphasizes the need for orthogonal probes. But the abstract-depth evidence does not address ongoing clinical development of zavondemstat or clinical-development consequences. The story’s hedging helps, but the clinical-development implication remains beyond what is verifiable from the supplied abstract profile.

1

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”
2

Study evidence

The orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352 in glioblastoma cellular assays; this supports that QC6352/zavondemstat's antiproliferative efficacy is driven primarily by DHODH inhibition.

“the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352.”
Claim 3 of 5Not coveredThe researchers also developed new compounds that inhibit KDM4 without affecting DHODH, which could help scientists study KDM4 more accurately in future cancer research.View evidenceHide evidence

Why this verdict

The abstract-level profile reports use of an orthogonal KDM4 inhibitor, ML324, that lacks DHODH inhibition and fails to phenocopy QC6352, supporting the need for orthogonal probes. It does not say the researchers developed new KDM4-selective compounds. That development claim may be present in the full paper, but it is not verifiable from the supplied abstract-depth profile.

1

Study evidence

The orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352 in glioblastoma cellular assays; this supports that QC6352/zavondemstat's antiproliferative efficacy is driven primarily by DHODH inhibition.

“the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352.”
Claim 4 of 5SupportedThe study found that zavondemstat and the related research compound QC6352 do not primarily target KDM4; instead, both compounds largely work by blocking DHODH.View evidenceHide evidence

Why this verdict

This matches the paper profile’s central abstract-level finding: QC6352 and zavondemstat are described as dual KDM4–DHODH inhibitors, with efficacy in glioblastoma models independent of KDM4 inhibition and DHODH inhibition identified as the dominant driver of antiproliferative activity. The wording should be understood as a functional mechanism claim, not as saying the compounds have no KDM4 activity at all.

1

Study evidence

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”
2

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”
Claim 5 of 5SupportedThe discovery emerged from research investigating whether zavondemstat and QC6352 could be repurposed for glioblastoma.View evidenceHide evidence

Why this verdict

The profile states that the study investigated whether QC6352 and its clinical analog zavondemstat exert antiglioblastoma effects through KDM4 inhibition or another target, using glioblastoma models. The exact word “repurposed” is not established in the abstract profile, but the core claim that the discovery arose from testing these compounds in a glioblastoma context is supported.

1

Study evidence

QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.

“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”
2

Study evidence

DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.

“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The paper characterizes QC6352 and zavondemstat as dual KDM4–DHODH inhibitors, not simply as compounds with no KDM4 activity.

    The story’s simplified phrasing captures the DHODH-dominant mechanism but may leave readers with the impression that KDM4 activity is absent or irrelevant in all senses. The abstract profile’s more precise framing is dual inhibition with DHODH as the dominant functional driver in the tested glioblastoma models.

    From in vitro chemical biology target identification/validation; orthogonal probe phenocopy comparison

  • Functional rescue evidence—uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogating growth inhibition—is a key support for DHODH as the functional target.

    The story generally mentions mechanistic or molecular work, but the presented claims and caveats do not specifically reflect these two rescue experiments, which are material to the strength of the mechanism claim.

    From in_vitro cell-based rescue assays

  • The orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, failed to phenocopy QC6352, supporting the conclusion that KDM4 inhibition alone does not explain the antiproliferative effect.

    The story gestures toward KDM4-selective tools in claim c5, but the supplied abstract profile describes ML324 as an orthogonal comparator rather than newly developed compounds, and the specific failure-to-phenocopy evidence is not accurately reflected.

    From orthogonal probe phenocopy comparison

3 things the story did carry across
  • The paper’s central mechanistic contribution is that QC6352 and zavondemstat’s antiproliferative activity in glioblastoma models is independent of KDM4 inhibition and is driven primarily by DHODH inhibition.
  • The evidence described in the supplied paper profile is preclinical, primarily in vitro glioblastoma stem-cell/cellular model work, not a patient-outcome or clinical trial study.
  • The supplied abstract profile does not establish clinical applicability, in vivo efficacy, clinical-trial status, or consequences for ongoing zavondemstat development.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

4

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroIdentify DHODH as the functional target that drives the antiproliferative activity of QC6352/zavondemstat in glioblastoma models and establish functional rescue evidence (uridine; inhibitor-resistant DHODH mutant).in vitro chemical biology target identification/validationExpand

In plain English

Using chemical biology approaches in glioblastoma models, the paper reports that dihydroorotate dehydrogenase (DHODH) — rather than KDM4 — is the functional cellular target responsible for the antiproliferative activity of QC6352 and its clinical analog zavondemstat. Functional rescue by uridine and by expression of an inhibitor‑resistant DHODH mutant abolished growth inhibition, while an orthogonal KDM4 inhibitor (ML324) that does not inhibit DHODH failed to phenocopy QC6352. The authors conclude QC6352 and zavondemstat are dual KDM4–DHODH inhibitors and that DHODH inhibition is the dominant driver of their antiglioblastoma activity.

Key findings

  • DHODH is identified as the functional target driving the antiproliferative activity of QC6352 and zavondemstat in glioblastoma models.
  • Uridine supplementation fully abrogates growth inhibition by QC6352/zavondemstat, supporting on-target DHODH inhibition.
“Instead, we identify dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine biosynthesis, as the functional target driving their antiproliferative activity.”
What this piece can’t prove

4 further details could not be confirmed from the summary.

2in vitroDetermine whether QC6352 (and its clinical analog zavondemstat) exerts antiglioblastoma effects through on-target KDM4 inhibition or via an alternative functional target.in vitro cell‑based chemical biology (GSC antiproliferative and rescue experiments)Expand

In plain English

In glioblastoma stem-cell models, the KDM4 chemical probe QC6352 and its clinical analog zavondemstat show antiproliferative activity that the authors attribute to inhibition of dihydroorotate dehydrogenase (DHODH) rather than on-target KDM4 inhibition. Uridine supplementation and expression of an inhibitor‑resistant DHODH mutant reportedly fully abrogate the growth inhibition, while an orthogonal KDM4 inhibitor (ML324), which lacks DHODH activity, does not phenocopy QC6352. The authors conclude QC6352 and zavondemstat act as dual KDM4–DHODH inhibitors with DHODH inhibition the dominant driver of antiglioblastoma efficacy.

Key findings

  • QC6352 and its clinical analog zavondemstat produce antiproliferative activity in glioblastoma stem‑cell models.
  • The antiproliferative efficacy of QC6352/zavondemstat is independent of KDM4 inhibition.
“Using comprehensive chemical biology approaches in glioblastoma models, we demonstrate that the efficacy of QC6352 and that of its clinical analog zavondemstat are independent of KDM4 inhibition.”
What this piece can’t prove
  • Summary is based solely on the paper abstract provided; full experimental details, data, and supporting figures are not available in the supplied text.
  • Inference about mechanism relies on author's reported rescue and comparator experiments; the abstract does not present raw data or methodological specifics needed to assess robustness or reproducibility.

2 further details could not be confirmed from the summary.

3in vitroIdentify DHODH as the functional target that drives the antiproliferative activity of QC6352/zavondemstat in glioblastoma models and establish functional rescue evidence (uridine; inhibitor-resistant DHODH mutant).in vitro cell-based rescue assaysExpand

In plain English

Abstract reports two independent functional rescue experiments — metabolic (uridine supplementation) and genetic (expression of an inhibitor-resistant DHODH mutant) — that fully abrogate QC6352/zavondemstat-mediated growth inhibition in glioblastoma models, supporting DHODH as the functional target driving the compounds' antiproliferative activity.

Key findings

  • Two independent rescue modalities — uridine supplementation and expression of an inhibitor-resistant DHODH mutant — fully abrogate QC6352/zavondemstat-mediated growth inhibition in glioblastoma models, implicating DHODH as the functional target driving antiproliferative activity.
“Uridine supplementation and expression of an inhibitor-resistant DHODH mutant fully abrogate growth inhibition”
What this piece can’t prove
  • Summary is based solely on the abstract; experimental methods and full data (cell lines, concentrations, timepoints, replicates, statistical analyses) are not provided here.
  • Abstract does not provide mechanistic readouts (e.g., pyrimidine nucleotide measurements) that would further substantiate the biochemical link between DHODH inhibition and growth phenotype.

2 further details could not be confirmed from the summary.

4in vitroDemonstrate lack of phenocopy by an orthogonal KDM4 inhibitor (ML324) that lacks DHODH inhibition, supporting DHODH-dominant mechanism and the need for orthogonal probes in cellular MOA assignment.orthogonal probe phenocopy comparisonExpand

In plain English

In glioblastoma cellular models (including glioblastoma stem cells), the orthogonal KDM4 inhibitor ML324 — reported to lack DHODH inhibition — did not reproduce (phenocopy) the antiproliferative effect of QC6352. This observation, reported alongside evidence that QC6352 and its clinical analog zavondemstat inhibit DHODH and that DHODH perturbation (uridine rescue and inhibitor-resistant DHODH) abrogates growth inhibition, supports the interpretation that DHODH inhibition is the dominant driver of QC6352's antiglioblastoma cellular efficacy and illustrates the need for orthogonal chemical probes in assigning cellular mechanism of action.

Key findings

  • The orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352 in glioblastoma cellular assays; this supports that QC6352/zavondemstat's antiproliferative efficacy is driven primarily by DHODH inhibition.
“the orthogonal KDM4 inhibitor ML324, which lacks DHODH inhibition, fails to phenocopy QC6352.”
What this piece can’t prove

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Open the paper in Tessa

DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells

Nature Chemical Biology · 2026

Source record (opens in a new tab)

Why this one

Near certain

NewsLink found the paper. Tessa is where you inspect it deeply.

Papers considered

The selected paper, plus nearby candidates.

Crossref, Europe PMC, PubMed · 39 candidate papers

Selected

DHODH is the key target of the KDM4 inhibitor QC6352 in glioblastoma stem cells

Nature Chemical Biology · 2026 · Crossref

Source (opens in a new tab)

And 33 more candidates considered.